The medicinal chemistry of botulinum, ricin and anthrax toxins

被引:27
作者
Hicks, RP [1 ]
Hartell, MG [1 ]
Nichols, DA [1 ]
Bhattacharjee, AK [1 ]
van Hamont, JE [1 ]
Skillman, DR [1 ]
机构
[1] Walter Reed Army Inst Res, Dept Med Chem, Div Expt Therapeut, Washington, DC 20307 USA
关键词
D O I
10.2174/0929867053202223
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The potential use of weapons of mass destruction (nuclear, biological or chemical) by terrorist organizations represents a major threat to world peace and safety. Only a limited number of vaccines are available to protect the general population from the medical consequences of these weapons. In addition there are major health concerns associated with a pre-exposure mass vaccination of the general population. To reduce or eliminate the impact of these terrible threats, new drugs must be developed to safely treat individuals exposed to these agents. A review of all therapeutic agents under development for the treatment of the illnesses and injuries that result from exposure to nuclear, biological or chemical warfare agents is beyond the scope of any single article. The intent here is to provide a focused review for medicinal and organic chemists of three widely discussed and easily deployed biological warfare agents, botulinum neurotoxin and ricin toxins and the bacteria Bacillus anthracis. Anthrax will be addressed because of its similarity in both structure and mechanism of catalytic activity with botulinum toxin. The common feature of these three agents is that they exhibit their biological activity via toxin enzymatic hydrolysis of a specific bond in their respective substrate molecules. A brief introduction to the history of each of the biological warfare agents is presented followed by a discussion on the mechanisms of action of each at the molecular level, and a review of current potential inhibitors under investigation.
引用
收藏
页码:667 / 690
页数:24
相关论文
共 152 条
[61]   Anthrax as a biological weapon - Medical and public health management [J].
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Friedlander, AM ;
Hauer, J ;
McDade, J ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (18) :1735-1745
[62]  
JANSONIUS JN, 1987, CRYSTALLOGR MOL BIOL, V126, P229
[63]   STRUCTURE OF RICIN A-CHAIN AT 2.5-A [J].
KATZIN, BJ ;
COLLINS, EJ ;
ROBERTUS, JD .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1991, 10 (03) :251-259
[64]  
KIFNER J, 1995, NY TIMES 1223, pA7
[65]   ANALYSIS OF SEVERAL KEY ACTIVE-SITE RESIDUES OF RICIN-A CHAIN BY MUTAGENESIS AND X-RAY CRYSTALLOGRAPHY [J].
KIM, Y ;
ROBERTUS, JD .
PROTEIN ENGINEERING, 1992, 5 (08) :775-779
[66]   Complications with the use of botulinum toxin [J].
Klein, AW .
DERMATOLOGIC CLINICS, 2004, 22 (02) :197-+
[67]  
KORTEPETER M, 2000, BLUE BOOK MED MANAGE
[68]   Crystal structure of botulinum neuro-toxin type A and implications for toxicity [J].
Lacy, DB ;
Tepp, W ;
Cohen, AC ;
DasGupta, BR ;
Stevens, RC .
NATURE STRUCTURAL BIOLOGY, 1998, 5 (10) :898-902
[69]  
Li L, 2000, BIOCHEMISTRY-US, V39, P10581, DOI 10.1021/bi0007472
[70]   ENZYMATIC CATALYSIS AND TRANSITION-STATE THEORY [J].
LIENHARD, GE .
SCIENCE, 1973, 180 (4082) :149-154